GBA HOLDINGS (00261) has completed the placement of 46.56 million shares, raising approximately HK$8.66 million.
GBA Group (00261) announced that all conditions set forth in the placement agreement have been met and the placement has been completed on August 26, 2026. According to the terms and conditions of the placement agreement, the placement agent has placed a total of 46.56 million shares at a placement price of HKD 0.20 per share to no less than six placees, representing approximately 14.05% of the enlarged issued capital of the Company following the completion of the placement and issuance of the placed shares.
GBA HOLDINGS (00261) announced that all conditions set out in the placement agreement have been fulfilled, and the placement has been completed on August 26, 2026. According to the terms and conditions of the placement agreement, the placement agent has placed a total of 46.56 million placement shares at the placement price of HKD 0.20 per share to no fewer than six placing investors, accounting for approximately 14.05% of the enlarged issued share capital of the company immediately following the completion of the placement.
The net proceeds from the placement, after deducting the placement commission and other related expenses (including professional fees), are estimated to be approximately HKD 8.66 million, equivalent to a net issue price of approximately HKD 0.186 per placement share. The company intends to use approximately 30% for expanding the Group's financial services; approximately 50% for expanding the Group's corporate advisory services through its subsidiary Naval Assessment Consultancy Limited; and approximately 20% for the Group's general working capital.
Related Articles

CSPC PHARMA (01093): The Phase III clinical study of SYS6010 for EGFR mutation-positive locally advanced or metastatic NSCLC that has failed EGFR TKI treatment has reached its pre-set primary endpoint.

CHINA ALUMCAN (06898) canceled a total of 22.646 million repurchased shares on August 26.

CHI PEOPLE HOLD (00681) announced its interim results, with a profit attributable to shareholders of 51.579 million yuan, a year-on-year decrease of 19.65%.
CSPC PHARMA (01093): The Phase III clinical study of SYS6010 for EGFR mutation-positive locally advanced or metastatic NSCLC that has failed EGFR TKI treatment has reached its pre-set primary endpoint.

CHINA ALUMCAN (06898) canceled a total of 22.646 million repurchased shares on August 26.

CHI PEOPLE HOLD (00681) announced its interim results, with a profit attributable to shareholders of 51.579 million yuan, a year-on-year decrease of 19.65%.

RECOMMEND





